CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity

被引：13

作者：

Roustit, M. ^{[1
,2
]}

Fonrose, X. ^{[3
]}

Montani, D. ^{[4
,5
]}

Girerd, B. ^{[4
,5
]}

Stanke-Labesque, F. ^{[2
,3
]}

Gonnet, N. ^{[2
]}

Humbert, M. ^{[4
,5
]}

Cracowski, J-L ^{[1
,2
]}

机构：

[1] Univ Grenoble Alpes, INSERM UMR HP2 1042, Grenoble, France

[2] Grenoble Univ Hosp, Clin Pharmacol Unit, INSERM CIC1406, Grenoble, France

[3] Grenoble Univ Hosp, Lab Pharmacol, Grenoble, France

[4] Univ Paris Sud, AP HP, Ctr Natl Reference Hypertens Pulm Severe,DHU, Thorax Innovat TORINO,Hop Bicetre,Serv Pneumol, F-94275 Le Kremlin Bicetre, France

[5] Ctr Chirurg Marie Lannelongue, LabEx LERMIT, INSERM UMRS 999, Le Plessis Robinson, France

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷 / 06期

关键词：

MECHANISM; INHIBITION; EXPORT;

D O I：

10.1038/clpt.2014.42

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Bosentan is an endothelin receptor antagonist used as a first-line treatment in pulmonary arterial hypertension (PAH). Its main adverse effect is a dose-dependent liver toxicity. CYP2C9*2 has recently been shown to be associated with hepatotoxicity in PAH patients. We conducted a nested case-control study to further explore the relationship between functional polymorphisms of gene products involved in bosentan pharmacokinetics (OATP1B1, OATP1B3, and CYP2C9) or hepatobiliary transporters affected by bosentan (ABCB11) and bosentan-induced liver toxicity.

引用

页码：583 / 585

页数：3

共 50 条

[31] An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
A G Vandell
J Lee
M Shi
I Rubets
K S Brown
J R Walker
The Pharmacogenomics Journal, 2018, 18 : 153 - 159
[32] An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
Vandell, A. G.
Lee, J.
Shi, M.
Rubets, I.
Brown, K. S.
Walker, J. R.
PHARMACOGENOMICS JOURNAL, 2018, 18 (01): : 153 - 159
[33] Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy
Sharma, Parul
Singh, Navneet
Sharma, Siddharth
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) : 2049 - 2067
[34] 一例Rotor综合征SLCO1B1和SLCO1B3基因突变分析
张志华
郑必霞
李玫
金玉
林谦
肝脏, 2016, 21 (07) : 542 - 544+605
[35] Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
Lonnberg, K. Ivar
Tornio, Aleksi
Hirvensalo, Paivi
Keskitalo, Jenni
Mustaniemi, Anna-Liina
Kiiski, Johanna I.
Filppula, Anne M.
Niemi, Mikko
PHARMACOGENETICS AND GENOMICS, 2023, 33 (07): : 153 - 160
[36] Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients
Lee, Hon-Kit
Hu, Miao
Lui, Sandra S. H.
Ho, Chung-Shun
Wong, Chun-Kwok
Tomlinson, Brian
PHARMACOGENOMICS, 2013, 14 (11) : 1283 - 1294
[37] 儿童Rotor综合征临床特点及SLCO1B1和SLCO1B3基因突变分析
叶家卫
谭丽梅
杨峰霞
徐翼
李旭芳
广州医药, 2021, 52 (06) : 1 - 5
[38] The Role of SLCO1B1, ABCB1, and CHRNA1 Gene Polymorphisms on the Efficacy of Rocuronium in Chinese Patients
Mei, Yang
Wang, Sai-Ying
Li, Yang
Yi, Shuang-Qiang
Wang, Chun-Yan
Yang, Mi
Duan, Kai-Ming
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (03): : 261 - 268
[39] Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs
Kim, Sang-Hoon
Kim, Sang-Heon
Lee, Jae-Hyung
Lee, Byoung-Hoon
Kim, Youn-Seup
Park, Jae-Seuk
Jee, Young-Koo
TUBERCULOSIS, 2012, 92 (01) : 100 - 104
[40] SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
Rattanacheeworn, Punyabhorn
Chamnanphon, Monpat
Thongthip, Siriwan
Kittanamongkolchai, Wonngarm
Townamchai, Natavudh
Avihingsanon, Yingyos
Udomnilobol, Udomsak
Prueksaritanont, Thomayant
Jianmongkol, Suree
Chariyavilaskul, Pajaree
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 521 - 530

← 1 2 3 4 5 →